United States Defends Falsity Theory, Use of Debatable Sub-Regulatory Guidance in Medicare Advantage False Claims Act Suit Against Kaiser Permanente
- September 16, 2022
- John Kelly , Barnes & Thornburg LLP
- Jacquelyn Papish , Barnes & Thornburg LLP
- A.J. Bolan , Barnes & Thornburg LLP
The False Claims Act actions pending against the Kaiser Permanente Consortium members in the U.S. District Court for the Northern District of California concerning Kaiser’s Medicare Advantage risk-adjustment practices are teeing up a possible showdown regarding what constitutes sub-regulatory guidance and when sub-regulatory guidance can support a legal falsity claim.
You must be logged in to access this content.